OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.
- 53% unit sales growth and 44% revenue increase in FY26
- TRIPP-FFX trial met co-primary endpoints supporting label expansion
- FDA Humanitarian Device Exemption application enters final review
- TGA approval enables Australian commercial launch
- Italian ethics approval simplifies procurement and market expansion
Strong Commercial Momentum Drives Sales Growth
OncoSil Medical (ASX:OSL) delivered a robust commercial performance in FY26, with unit sales surging 53% and revenue climbing 44% year-on-year. This growth was fuelled by expanding adoption across European markets, where new treatment centres and increased utilisation at existing sites have bolstered the company’s footprint. The company anticipates reaching approximately 50 active centres globally by the end of 2026, despite a delay in the German G-BA clinical trial start.
TRIPP-FFX Trial Validates Clinical Value and Market Expansion
The TRIPP-FFX trial marked a pivotal clinical milestone by successfully meeting its co-primary endpoints of safety and 16-week local disease control in patients with unresectable locally advanced pancreatic cancer (LAPC). Adding OncoSil™ to the FOLFIRINOX chemotherapy regimen delivered an 82.2% local disease control rate and median overall survival of 18.3 months, maintaining a manageable safety profile. These results underpin the company’s plan to expand its European and UK product label to include FOLFIRINOX, aligning OncoSil™ with current treatment standards and potentially widening its commercial reach. The trial’s selection for a Rapid Oral Presentation at the prestigious ESMO GI 2026 conference further underscores its scientific and commercial significance.
FDA HDE Application Nears Approval, Opening US Market
OncoSil Medical advanced its US regulatory ambitions with the FDA confirming all outstanding queries on its Humanitarian Device Exemption (HDE) application for distal cholangiocarcinoma (dCCA) have been resolved. The submission entered the FDA’s targeted 45-day final review phase following the July 2 filing of the final package. Approval would enable commercialisation in the US for a rare cancer with limited treatment options, representing a major new revenue stream and validation of the company’s clinical strategy. This progress follows earlier regulatory milestones and is a critical inflection point for OncoSil’s US market entry plans. FDA HDE application final review
TGA Approval Unlocks Australian Market Potential
The Therapeutic Goods Administration (TGA) granted approval for OncoSil™ to treat unresectable LAPC in combination with gemcitabine-based chemotherapy. This regulatory green light, including listing on the Australian Register of Therapeutic Goods, establishes OncoSil™ as the first and only TGA-approved Class III medical device targeting pancreatic tumours. With an addressable Australian patient population of approximately 1,300 annually, this approval opens a new commercial market and validates the company’s regulatory approach in its home jurisdiction. The upcoming completion of a dedicated manufacturing facility in Sydney, developed with Cyclotek, is set to enhance domestic production capacity and global supply chain resilience. Australian production hub
Real-World Data and Italian Ethics Approval Strengthen Adoption
OncoSil Medical bolstered its clinical evidence base with real-world data from the OSPREY Registry and Spanish multi-centre experience presented at ESGE and ASCO congresses. These datasets demonstrated strong safety profiles, local disease control rates exceeding 90%, and encouraging survival outcomes, supporting increased physician confidence and uptake. A peer-reviewed study also confirmed the device’s highly localised mechanism, showing microparticles remain confined within tumour tissue, which may inform future dosing strategies.
In Italy, central ethics committee approval for the OSPRItaly registry reclassified it as an observational registry, allowing hospitals to procure OncoSil™ directly via simplified processes. This regulatory streamlining removes barriers to adoption and reimbursement, with the company targeting a doubling of authorised hospitals from four to eight in the first half of FY27, accelerating commercial rollout in one of Europe’s largest pancreatic cancer markets.
Financial Discipline Supports Strategic Growth Initiatives
OncoSil Medical ended Q4 FY26 with $6.5 million in cash, down from $9.3 million the prior quarter, reflecting ongoing investment in clinical trials, regulatory approvals, and commercial expansion. Customer receipts rose 179% year-on-year to $2.1 million for FY26, evidencing growing market traction. Research and development spend moderated as key trials entered close-out phases, with expectations for reduced outflows from mid-FY27. The company continues to prioritise sales growth in Europe, regulatory label expansions, manufacturing scale-up, and market launches in Australia and the US, balancing expenditure with strategic milestones.
Bottom Line?
OncoSil Medical’s clinical breakthroughs and regulatory advances set the stage for broader market penetration, but the timing of FDA approval and trial commencements in Germany remain key variables to watch.
Questions in the middle?
- Will FDA HDE approval materialise within the expected 45-day review window?
- How will the delayed G-BA trial commencement in Germany affect European expansion?
- Can the new Australian manufacturing facility improve margins and supply chain stability as planned?